$3.51
0.86% yesterday
Nasdaq, Sep 24, 10:00 pm CET
ISIN
US8051111016
Symbol
SVRA

Savara, Inc. Stock price

$3.51
+0.37 11.78% 1M
+0.68 24.03% 6M
+0.44 14.33% YTD
-0.91 20.59% 1Y
+2.15 158.09% 3Y
+2.38 210.62% 5Y
-28.29 88.96% 10Y
-5,666.49 99.94% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
+0.03 0.86%
ISIN
US8051111016
Symbol
SVRA
Industry

Key metrics

Basic
Market capitalization
$606.7m
Enterprise Value
$489.9m
Net debt
positive
Cash
$146.4m
Shares outstanding
172.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.0
Financial Health
Equity Ratio
80.5%
Return on Equity
-56.0%
ROCE
-78.2%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-117.3m | $-39.0m
EBIT
$-117.4m | $-119.0m
Net Income
$-110.3m | $-90.9m
Free Cash Flow
$-99.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-45.6% | 62.1%
EBIT
-45.5% | -15.6%
Net Income
-47.7% | 5.3%
Free Cash Flow
-38.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
10.9%
Employees
59
Rev per Employee
$0.0
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Savara, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Savara, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
67% 67%
-
- Research and Development Expense 84 84
37% 37%
-
-117 -117
46% 46%
-
- Depreciation and Amortization 0.13 0.13
8% 8%
-
EBIT (Operating Income) EBIT -117 -117
46% 46%
-
Net Profit -110 -110
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
PRNewsWire
about 20 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-...
Neutral
Business Wire
one day ago
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) investors of the November 7, 2025 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Savara securities between March 7, 2024 through May 23, 2025 (“the Class Period”). Follow the link below for more information: [CONT...
Neutral
PRNewsWire
one day ago
LOS ANGELES , Sept. 23, 2025 /PRNewswire/ -- The Law Offices of Frank R.
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today